tert-Butyl rosuvastatin
[CAS# 355806-00-7]

Identification

• Name: tert-Butyl rosuvastatin
• Synonyms: tert-Butyl (6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl)methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester
• Molecular Formula: C₂₆H₃₆FN₃O₆S
• Molecular Weight: 537.64
• CAS Registry Number: 355806-00-7
• EC Number: 609-144-4
• SMILES: CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)OC(C)(C)C)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

Properties

• Density: 1.259

Safety Data

• Hazard Symbols: GHS08;GHS09 Danger
• Hazard Statements: H360-H360D-H373-H400
• Precautionary Statements: P203-P260-P273-P280-P318-P319-P391-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Reproductive toxicity	Repr.	1B	H360
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400

Discovory and Applicatios

tert-Butyl rosuvastatin, a derivative of the statin medication rosuvastatin, was developed as a more stable and soluble form of the original compound. The discovery of tert-Butyl rosuvastatin emerged from the continuous efforts to enhance the pharmacological properties of statins for better therapeutic outcomes. By introducing the tert-butyl group, researchers aimed to improve the compound's bioavailability and efficacy while maintaining its cholesterol-lowering effects. The synthesis of tert-Butyl rosuvastatin marked a significant advancement in drug development, providing a promising alternative for patients who may benefit from rosuvastatin therapy.

tert-Butyl rosuvastatin, like its parent compound rosuvastatin, is primarily used for the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis, thereby lowering LDL cholesterol levels and reducing the risk of cardiovascular events such as heart attacks and strokes.

As a potent cholesterol-lowering agent, tert-Butyl rosuvastatin plays a crucial role in the prevention of cardiovascular diseases. By lowering LDL cholesterol levels, it helps prevent the buildup of plaque in the arteries, reducing the risk of atherosclerosis and coronary artery disease. Additionally, it may have anti-inflammatory and antioxidant properties that further protect against cardiovascular damage.

tert-Butyl rosuvastatin is also prescribed for the management of dyslipidemia, a condition characterized by abnormal levels of lipids (such as cholesterol and triglycerides) in the blood. By effectively lowering LDL cholesterol and triglyceride levels while increasing HDL cholesterol levels, it helps restore lipid balance and reduce the risk of cardiovascular complications associated with dyslipidemia.

For individuals with familial hypercholesterolemia, a genetic disorder characterized by high cholesterol levels from birth, tert-Butyl rosuvastatin can be an effective treatment option. It helps lower LDL cholesterol levels even in individuals with a genetic predisposition to high cholesterol, reducing the risk of premature cardiovascular disease and improving long-term outcomes.

In addition to its clinical applications, tert-Butyl rosuvastatin is also valuable in research and development efforts aimed at improving statin therapy. Scientists continue to explore novel formulations and delivery methods to enhance the efficacy, safety, and patient adherence to statin medications, including tert-Butyl rosuvastatin.